Lucentis
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Nonproliferative Diabetic Retinopathy
Conditions
Nonproliferative Diabetic Retinopathy
Trial Timeline
Aug 1, 2016 → Dec 1, 2019
NCT ID
NCT02834663About Lucentis
Lucentis is a approved stage product being developed by Novartis for Nonproliferative Diabetic Retinopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT02834663. Target conditions include Nonproliferative Diabetic Retinopathy.
What happened to similar drugs?
0 of 1 similar drugs in Nonproliferative Diabetic Retinopathy were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02834663 | Approved | Completed |
| NCT04847895 | Pre-clinical | Completed |
Competing Products
3 competing products in Nonproliferative Diabetic Retinopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Intravitreal aflibercept injection [IAI] + Sham | Regeneron Pharmaceuticals | Phase 3 | 40 |
| EYP-1901 | EyePoint Pharmaceuticals | Phase 2 | 29 |
| AKB-9778 + Placebo | EyePoint Pharmaceuticals | Phase 2 | 29 |